pSivida eyes Iluvian
Friday, 13 March, 2009
pSivida has reported good interim results in its Phase II study of the intra-vitreal insert Iluvien.
The 36-month open label study is being conducted by pSivida’s licensing partner Alimera Sciences and is being run concurrently with a Phase III trial of a corticosteroid in patients with diabetic macular oedema.
Data from the first 12 months showed no adverse events in lose dose patients while there was a small increase in intra-ocular pressure in high dose patients.
Iluvian delivers the drug fluocinolone acetonide directly into the eye. pSivida has licensed two other ophthalmic products, Retisert and Vitrasert, to Bausch & Lomb.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
